type 2 diabetes
Conditions
Interventions
lilaglutide 0.9mg/day sc
lilaglutide 0.3mg/day sc In case with inadequate control after 3 months therapy with 0.3mg of lilaglutide, dose has to be increased to 0.9mg/day.
50mg of sitagliptin p.o
Sponsors
Department of Metabolism and Endocrinology, Juntendo Graduate University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes patients treated with DPP-4 inhibitor and (1)their HbA1c is more than 7.5% (2)thier duration of therapy with DPP-4 inhibitor is more than 6 months. (3)who can understand and agree with informed consent.
Exclusion criteria
Exclusion criteria: 1)patients who come under contraindicaion for GLP-1 receptor agonist. 2) patients who come under careful administration for GLP-1 receptor agonist 3)patients with cancer 4)anemic patients (Hb is less than 11g/dL) 5) patients with thrombocytepenia (Platelet count is less than 100000/mm3) 6) patients with serious diabetic complications including progressed neutopathy and proliferative retinopathy 7) patietns with serious infection, inflammation, or injuary. pre- or post- operative state 8) patients who are pregnant, hope to be pregnant, or are in lactation period 9) patients who are not applicable to this study judged by the medical doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change of glycated hemoglobin from baseline to after 6 months | — |
Countries
Japan
Outcome results
None listed